Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 14/20 | 0.72 |
| ▸ | TP53 | P04637 | 10/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9984557 | 0.94 | MAPT (0.69) | MAPTTP53SMN1; SMN2KDM4ELMNA | |
| SCHEMBL9983609 | 0.93 | MAPT (0.68) | MAPTTP53SMN1; SMN2KDM4ELMNA | |
| SCHEMBL9983406 | 0.90 | MAPT (0.59) | MAPTTP53SMN1; SMN2KDM4ELMNA | |
| SCHEMBL9983988 | 0.88 | MAPT (0.59) | MAPTTP53SMN1; SMN2KDM4ELMNA | |
| SCHEMBL9983497 | 0.88 | MAPT (0.81) | MAPTTP53SMN1; SMN2KDM4ELMNA | |
| SCHEMBL9983349 | 0.87 | HSD11B1 (0.59) | MAPTTP53SMN1; SMN2KDM4ELMNA | |
| SCHEMBL12041852 | 0.87 | HSD11B1 (0.67) | MAPTTP53SMN1; SMN2POLBGAA | |
| SCHEMBL9983636 | 0.86 | MAPT (0.67) | MAPTTP53SMN1; SMN2KDM4ELMNA | |
| SCHEMBL12041846 | 0.86 | HSD11B1 (0.61) | MAPTTP53SMN1; SMN2KDM4ELMNA | |
| SCHEMBL12041807 | 0.85 | MAPT (0.74) | MAPTTP53SMN1; SMN2POLBHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187438-B2 | Derivatives of benzothiazines, preparation thereof and application thereof as drugs | PIERRE FABRE MEDICAMENT (FR) | 2015-11-17 | — | — | US | claimed |
| EP-2403840-B1 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS | PF MEDICAMENT (FR) | 2014-05-14 | — | — | EP | claimed |
| US-20110319326-A1 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS | PIERRE FABRE MEDICAMENT (FR) | 2011-12-29 | — | — | US | claimed |
| EP-2403840-B1 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS | PF MEDICAMENT (FR) | 2014-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319326-A1 | DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS | HSD11B1, CYP11B1, HSD17B11 | MAPT 4086/4885TP53 3851/4885SMN1; SMN2 3970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.